Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthias Grothe

Showing results (51-60 of 69) with videos related to

Pageof 7
Sort By:
Scientific Reports|May 16, 2026
The relationship between objective and subjective cognitive performance and clinical and MRI disease burden in early multiple sclerosisDelphine Van Laethem, Lars Costers, Augusto Miravalle, et al.
The International Journal of Eating Disorders|March 22, 2025
Increased Serum Neurofilament Light Chain Concentration Associated With Microglial Morphology Changes in Chronically-Starved MiceAnnelie Zimmermann, Hanna Rupprecht, Stephan Lang, et al.
Frontiers in Digital Health|March 30, 2026
Real-world federated learning for brain imaging scientistsStijn Denissen, Jorne Laton, Matthias Grothe, et al.
European Journal of Neurology|June 23, 2022
Brain age as a surrogate marker for cognitive performance in multiple sclerosisStijn Denissen, Denis Alexander Engemann, Alexander De Cock, et al.
Frontiers in Immunology|February 14, 2025
Apheresis for the treatment of relapses in MS and NMOSD: reduced antibody reactivities, gene expression changes and potential clinical response indicatorsMichael Hecker, Brit Fitzner, Isis Ludwig-Portugall, et al.
Annals of Neurology|November 25, 2024
Different Treatment Outcomes of Multiple Sclerosis Patients Receiving Ocrelizumab or OfatumumabSven G Meuth, Stephanie Wolff, Anna Mück, et al.
Neurological Research and Practice|November 6, 2022
Real-world evidence on siponimod treatment in patients with secondary progressive multiple sclerosisLiesa Regner-Nelke, Marc Pawlitzki, Alice Willison, et al.
European Journal of Neurology|February 4, 2026
Age, Low Immunoglobulin G, and M Serum Levels Predict Infections in People With AQP4-IgG+ NMOSD Treated With Rituximab-A Multicenter Cohort Study From the German Neuromyelitis Optica Study Group (NEMOS)Daniel Engels, Mariella Herfurth, Joachim Havla, et al.
Annals of Neurology|December 30, 2021
Subcortical Volumes as Early Predictors of Fatigue in Multiple SclerosisVinzenz Fleischer, Dumitru Ciolac, Gabriel Gonzalez-Escamilla, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|July 31, 2024
Cognition in patients with myelin oligodendrocyte glycoprotein antibody-associated disease: a prospective, longitudinal, multicentre study of 113 patients (CogniMOG-Study)Sarah Passoke, Carlotta Stern, Vivien Häußler, et al.
Pageof 7

Showing results (51-60 of 69) with videos related to

Sort By:
Pageof 7
Scientific Reports|May 16, 2026
The relationship between objective and subjective cognitive performance and clinical and MRI disease burden in early multiple sclerosisDelphine Van Laethem, Lars Costers, Augusto Miravalle, et al.
The International Journal of Eating Disorders|March 22, 2025
Increased Serum Neurofilament Light Chain Concentration Associated With Microglial Morphology Changes in Chronically-Starved MiceAnnelie Zimmermann, Hanna Rupprecht, Stephan Lang, et al.
Frontiers in Digital Health|March 30, 2026
Real-world federated learning for brain imaging scientistsStijn Denissen, Jorne Laton, Matthias Grothe, et al.
European Journal of Neurology|June 23, 2022
Brain age as a surrogate marker for cognitive performance in multiple sclerosisStijn Denissen, Denis Alexander Engemann, Alexander De Cock, et al.
Frontiers in Immunology|February 14, 2025
Apheresis for the treatment of relapses in MS and NMOSD: reduced antibody reactivities, gene expression changes and potential clinical response indicatorsMichael Hecker, Brit Fitzner, Isis Ludwig-Portugall, et al.
Annals of Neurology|November 25, 2024
Different Treatment Outcomes of Multiple Sclerosis Patients Receiving Ocrelizumab or OfatumumabSven G Meuth, Stephanie Wolff, Anna Mück, et al.
Neurological Research and Practice|November 6, 2022
Real-world evidence on siponimod treatment in patients with secondary progressive multiple sclerosisLiesa Regner-Nelke, Marc Pawlitzki, Alice Willison, et al.
European Journal of Neurology|February 4, 2026
Age, Low Immunoglobulin G, and M Serum Levels Predict Infections in People With AQP4-IgG+ NMOSD Treated With Rituximab-A Multicenter Cohort Study From the German Neuromyelitis Optica Study Group (NEMOS)Daniel Engels, Mariella Herfurth, Joachim Havla, et al.
Annals of Neurology|December 30, 2021
Subcortical Volumes as Early Predictors of Fatigue in Multiple SclerosisVinzenz Fleischer, Dumitru Ciolac, Gabriel Gonzalez-Escamilla, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|July 31, 2024
Cognition in patients with myelin oligodendrocyte glycoprotein antibody-associated disease: a prospective, longitudinal, multicentre study of 113 patients (CogniMOG-Study)Sarah Passoke, Carlotta Stern, Vivien Häußler, et al.
Pageof 7